Levocabastine

Levocabastine

Systematic (IUPAC) name
(3S,4R)-1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic acid
Clinical data
Trade names	Livostin
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Legal status	℞ (Prescription only)
Routes of administration	Ophthalmic, intranasal
Identifiers
CAS Number	79516-68-0 Y
ATC code	R01AC02 (WHO) S01GX02
PubChem	CID: 54385
IUPHAR/BPS	1586
DrugBank	DB01106 Y
ChemSpider	16736421 Y
UNII	H68BP06S81 Y
KEGG	D08117 Y
ChEMBL	CHEMBL1201312 N
Chemical data
Formula	C26H29FN2O2
Molecular mass	420.519 g/mol
SMILES Fc1ccc(cc1)[C@]2(CC[C@@H](CC2)N3CC[C@@]([C@H](C)C3)(c4ccccc4)C(O)=O)C#N
InChI InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23-,25-,26-/m1/s1 Y Key:ZCGOMHNNNFPNMX-KYTRFIICSA-N Y
NY (what is this?)  (verify)

Levocabastine (trade name Livostin) is a selective second-generation H₁ receptor antagonists which was discovered at Janssen Pharmaceutica in 1979. It is used for allergic conjunctivitis.

As well as acting as an antihistamine, levocabastine has also subsequently been found to act as a potent and selective antagonist for the neurotensin receptor NTS₂, and was the first drug used to characterise the different neurotensin subtypes. This has made it a useful tool for the study of this receptor.

The pharmaceutical drug Bilina is a combination of Levocabastine, benzalkonium chloride, and other components and is typically used in a 0.5 mg/ml suspension as eye-drops, dispensed in 4ml bottles for the treatment of allergic conjunctivitis or similar allergic ocular conditions.

External links

1. REDIRECT Template:Peptide receptor modulators